Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial.
Ghrelin
Stress
Transcutaneous cervical vagus nerve stimulation
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
received:
20
06
2023
revised:
22
08
2023
accepted:
08
09
2023
pmc-release:
01
12
2024
medline:
4
10
2023
pubmed:
16
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
Transcutaneous cervical vagus nerve stimulation (tcVNS) has emerged as a potential treatment strategy for patients with stress-related psychiatric disorders. Ghrelin is a hormone that has been postulated to be a biomarker of stress. While the mechanisms of action of tcVNS are unclear, we hypothesized that tcVNS reduces the levels of ghrelin in response to stress. Using a randomized double-blind approach, we studied the effects of tcVNS on ghrelin levels in individuals with a history of exposure to traumatic stress. Participants received either sham (n = 29) or active tcVNS (n = 26) after exposure to acute personalized traumatic script stress and mental stress challenges (public speech, mental arithmetic) over a three day period. There were no significant differences in the levels of ghrelin between the tcVNS and sham stimulation groups at either baseline or in the absence of trauma scripts. However, tcVNS in conjunction with personalized traumatic scripts resulted in lower ghrelin levels compared to the sham stimulation group (265.2 ± 143.6 pg/ml vs 478.7 ± 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental arithmetic tests, ghrelin levels were found to be lower in the group receiving tcVNS compared to the sham group (293.3 ± 102.4 pg/ml vs 540.3 ± 203.9 pg/ml, P = 0.009). Timing of ghrelin measurements, and stimulation of only left vagus nerve. tcVNS decreases ghrelin levels in response to various stressful stimuli. These findings are consistent with a growing literature that tcVNS modulates hormonal and autonomic responses to stress.
Sections du résumé
BACKGROUND
Transcutaneous cervical vagus nerve stimulation (tcVNS) has emerged as a potential treatment strategy for patients with stress-related psychiatric disorders. Ghrelin is a hormone that has been postulated to be a biomarker of stress. While the mechanisms of action of tcVNS are unclear, we hypothesized that tcVNS reduces the levels of ghrelin in response to stress.
METHODS
Using a randomized double-blind approach, we studied the effects of tcVNS on ghrelin levels in individuals with a history of exposure to traumatic stress. Participants received either sham (n = 29) or active tcVNS (n = 26) after exposure to acute personalized traumatic script stress and mental stress challenges (public speech, mental arithmetic) over a three day period.
RESULTS
There were no significant differences in the levels of ghrelin between the tcVNS and sham stimulation groups at either baseline or in the absence of trauma scripts. However, tcVNS in conjunction with personalized traumatic scripts resulted in lower ghrelin levels compared to the sham stimulation group (265.2 ± 143.6 pg/ml vs 478.7 ± 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental arithmetic tests, ghrelin levels were found to be lower in the group receiving tcVNS compared to the sham group (293.3 ± 102.4 pg/ml vs 540.3 ± 203.9 pg/ml, P = 0.009).
LIMITATIONS
Timing of ghrelin measurements, and stimulation of only left vagus nerve.
CONCLUSION
tcVNS decreases ghrelin levels in response to various stressful stimuli. These findings are consistent with a growing literature that tcVNS modulates hormonal and autonomic responses to stress.
Identifiants
pubmed: 37714385
pii: S0165-0327(23)01143-6
doi: 10.1016/j.jad.2023.09.015
pmc: PMC10698687
mid: NIHMS1934644
pii:
doi:
Substances chimiques
Ghrelin
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-90Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL130025
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf and declare that J.D·B has research funding support from ElectroCore LLC for the submitted work. Both active and sham stimulation devices used in this study were provided by ElectroCore free of charge. All remaining authors have no competing interests to report.
Références
Am J Psychiatry. 2017 Jul 1;174(7):640-648
pubmed: 28359201
Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):31-5
pubmed: 25440723
Appetite. 2014 Mar;74:35-43
pubmed: 24295926
Nutrients. 2021 Feb 27;13(3):
pubmed: 33673594
Dev Psychopathol. 2011 Aug;23(3):725-76
pubmed: 21756430
Am J Physiol Regul Integr Comp Physiol. 2001 May;280(5):R1483-7
pubmed: 11294772
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10434-9
pubmed: 15231997
Brain Behav Immun Health. 2020 Sep 11;9:100138
pubmed: 34589887
N Engl J Med. 2002 May 23;346(21):1623-30
pubmed: 12023994
Neurobiol Stress. 2020 Oct 20;13:100264
pubmed: 33344717
N Engl J Med. 1998 Jan 15;338(3):171-9
pubmed: 9428819
Am J Physiol Regul Integr Comp Physiol. 2009 May;296(5):R1358-65
pubmed: 19261914
Nat Neurosci. 2008 Jul;11(7):752-3
pubmed: 18552842
J Pers Med. 2020 Sep 09;10(3):
pubmed: 32916852
Brain Stimul. 2020 Jan - Feb;13(1):47-59
pubmed: 31439323
Nat Rev Neurosci. 2009 Jun;10(6):459-66
pubmed: 19339973
AMIA Annu Symp Proc. 2020 Mar 04;2019:1061-1070
pubmed: 32308903
Int J Neuropsychopharmacol. 2017 Sep 1;20(9):692-697
pubmed: 28911006
IEEE J Biomed Health Inform. 2020 Jul;24(7):1917-1925
pubmed: 32175881
Curr Drug Targets. 2016;17(5):495-507
pubmed: 25981609
Brain Stimul. 2013 Sep;6(5):798-804
pubmed: 23453934
Brain Stimul. 2020 Sep - Oct;13(5):1333-1348
pubmed: 32659483
Neuropsychopharmacology. 2006 Jul;31(7):1345-55
pubmed: 16641939
J Neural Transm (Vienna). 2017 Jan;124(1):145-158
pubmed: 27848034
Nature. 2011 Jun 22;474(7352):498-501
pubmed: 21697947
Brain Stimul. 2020 May - Jun;13(3):717-750
pubmed: 32289703
Compr Psychoneuroendocrinol. 2020 Oct 27;4:100012
pubmed: 35755625
Horm Behav. 2010 Sep;58(4):677-84
pubmed: 20540943
Endocr Connect. 2020 Feb;9(2):163-172
pubmed: 32045358
Psychoneuroendocrinology. 2007 Jul;32(6):693-702
pubmed: 17560728
Physiol Behav. 2019 Sep 1;208:112563
pubmed: 31145919
J Clin Invest. 2011 Jul;121(7):2684-92
pubmed: 21701068
J Psychiatry Neurosci. 2010 Mar;35(2):80-9
pubmed: 20184804
J Child Adolesc Psychopharmacol. 2016 Oct;26(8):733-739
pubmed: 26862938
Am J Psychiatry. 2017 Jul 1;174(7):609-610
pubmed: 28669203
Neurosci Lett. 2007 Oct 9;426(1):49-53
pubmed: 17884293
Eur J Endocrinol. 2004 Apr;150(4):447-55
pubmed: 15080773
Psychiatry Investig. 2014 Apr;11(2):167-72
pubmed: 24843372
Psychoneuroendocrinology. 2014 Oct;48:178-88
pubmed: 25032903
Transl Psychiatry. 2018 Apr 11;8(1):74
pubmed: 29643360
Epilepsia. 1994 May-Jun;35(3):627-36
pubmed: 8026409
Biol Psychiatry. 2005 Sep 1;58(5):364-73
pubmed: 16139582
JMIR Mhealth Uhealth. 2020 Sep 22;8(9):e20488
pubmed: 32960179